News
Therini Bio Announces Positive Preclinical Data Supporting the Development of THN391 in Neurodegenerative Ocular Diseases
THN391 demonstrated effectiveness in protecting against vascular and neuronal degeneration - Therini Bio plans to initiate a Phase 1/2a trial evaluating THN391 in DME in 2H24 - The data was presented at ARVO 2024 - Sacramento, May 8, 2024 (GLOBE NEWSWIRE) —...
Therini Bio Announces Interim Results from the Phase 1 Trial of THN391 for the Potential Treatment of Dementia
- THN391 was found to be safe and well-tolerated - - THN391 demonstrated a prolonged half-life and dose proportional Cmax levels - - The data will be presented October 25-27th at CTAD 2023 - Sacramento, October 24, 2023 (GLOBE NEWSWIRE) -- Therini Bio, Inc., a...
Therini Bio Initiates First-In-Human Dosing in Phase 1 Trial of THN391, a Fibrin-Targeting Therapeutic Candidate for Alzheimer’s Disease
- Industry Veteran Frank D. Lee Appointed as Executive Chairperson of the Board SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Therini Bio, Inc., a biotech company focused on developing fibrin targeted therapies to treat inflammatory neurodegenerative and...
Therini Bio Raises $36M Series A Financing to Develop Fibrin-Targeted Therapies for Neurodegenerative and Retinal Diseases
- Funding from top-tier syndicate will be used to advance potential first-in-class investigational antibody THN391 into clinical trials. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Therini Bio, Inc., a biotech company aimed at developing fibrin-targeted...
Therini Bio Secures $17 Million Investment to Advance Fibrin Therapeutic Candidates Towards the Clinic
SOUTH SAN FRANCISCO, Calif, May 10, 2021 /PRNewswire/ -- Therini Bio, Inc. announced it has completed an oversubscribed Seed Extension round of financing. The capital will accelerate the development of Therini's lead program – a monoclonal antibody against fibrin –...
MedaRed Announces Name Change to Therini Bio
Corporate Headquarters Relocated to Lilly Gateway Labs in South San FranciscoNEWS PROVIDED BYTherini Bio, Inc.Feb 24, 2020, 08:17 ET SOUTH SAN FRANCISCO, Calif., Feb. 24, 2020 /PRNewswire/ -- MedaRed, Inc., a vascular biology company focused initially on discovering...
MedaRed Raises $6.5 Million and Appoints Industry Leaders to Board of Directors, Top Management Roles
Daniel Burgess and Jeffrey Stavenhagen, PhD join leadership team NEWS PROVIDED BY MedaRed, Inc.Jul 08, 2019, 08:00 ET SAN FRANCISCO, July 8, 2019 /PRNewswire/ -- MedaRed, Inc., a biotechnology company focused on discovering and developing new therapeutics targeting...
